Weeks after dropping big response data, Amgen lines up priority review for KRAS hopeful sotorasib in NSCLC
Amgen is looking to go where no other drugmaker has gone before with the KRAS inhibitor sotorasib, which posted big Phase II lung cancer response …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.